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Macrophages clear pathogens and damaged or aged
cells from the blood stream via phagocytosis. Cell-
surface CD47 interacts with its receptor on macro-
phages, SIRPa, to inhibit phagocytosis of normal,
healthy cells. We find that mobilizing cytokines and
inflammatory stimuli cause CD47 to be transiently
upregulated on mouse hematopoietic stem cells
(HSCs) and progenitors just prior to and during
their migratory phase, and that the level of CD47 on
these cells determines the probability that they are
engulfed in vivo. CD47 is also constitutively upregu-
lated on mouse and human myeloid leukemias, and
overexpression of CD47 on a myeloid leukemia line
increases its pathogenicity by allowing it to evade
phagocytosis. We conclude that CD47 upregulation
is an important mechanism that provides protection
to normal HSCs during inflammation-mediatedmobi-
lization, and that leukemic progenitors co-opt this
ability in order to evade macrophage killing.
INTRODUCTION
Hematopoietic stem cells (HSCs) have the ability to migrate to
ectopic niches in fetal and adult life via the blood stream (Chris-
tensen et al., 2004; Cumano and Godin, 2007; Morrison et al.,
1995; Wright et al., 2001b). Once in the blood, HSCs home to
VCAM-1+ endothelia using integrin a4b1 (Wagers et al., 2002),
then navigate the vascular beds of the marrow, spleen, and liver
before returning to potential niches that secrete SDF-1, for which
HSCshave responsiveCXCR4chemokine receptors (Peledet al.,
1999;Wright et al., 2002).Macrophages lining vascular sinusoids
at these sites function to removedamaged cells and foreign parti-
cles from the blood stream, sensing altered surface molecules.
During inflammatory responses, macrophages become more
phagocytically active in order to more effectively clear offendingpathogens (Wright et al., 1989). At these times, host cells are at
increased risk of clearance and newly arriving stem cells might
require additional protection against phagocytosis.
Like normal HSCs, leukemic stem and progenitor cells also
havean intrinsicability tomigrateviacirculation toectopicmarrow
sites. By analogy with the normal HSCs, the leukemic stem cells
(LSCs) must also be able to navigate through macrophage-lined
vasculature of spleen, liver, and marrow as they travel to ectopic
niches.
CD47 isan immunoglobulin-likeprotein that is known to interact
functionally with integrins (Brown and Frazier, 2001) and thromb-
spondin-1 (Gaoet al., 1996; Liu et al., 2001). It hasbeen implicated
in functions as diverse as neutrophil migration (Lindberg et al.,
1996), axon extension (Miyashita et al., 2004), and T cell costimu-
lation (Reinhold et al., 1997). In addition, CD47 is capable of inter-
actingwith its receptorSIRPa (Jiang et al., 1999) onmacrophages
to negatively regulate phagocytosis (Brown and Frazier, 2001).
Lack of autonomous CD47 expression results in phagocytosis
of red blood cells (Oldenborg et al., 2000), as well as T cells and
whole bone marrow cells in a transplant setting (Blazar et al.,
2001). Thus, CD47 functions as a ‘‘don’t eat me’’ signal to ensure
that autologous cells are not inappropriately phagocytosed.
While the absence of CD47 is known to result in phagocytosis,
the effect of differential CD47 expression is unclear. IAP+/ plate-
lets and erythrocytes may be more prone to phagocytosis than
their wild-type counterparts (Olsson et al., 2005, 2007), which
suggests that CD47 downregulation might lead to clearance of
these cells as they age. However, no formal exploration of the role
of CD47 expression on normal or leukemic hematopoietic stem
andprogenitor cells,which are alsophysiologicallymigrating cells,
hasbeenundertaken.Hence,weperformedexperiments tounder-
stand the effect of differential CD47 expression on these cells.
RESULTS
CD47Expression Is Increased inHSCs afterMobilization
or Induced Inflammation
Mobilization ofmarrowstemandprogenitor cells involves several
steps in which they come into contact with macrophages. WeCell 138, 271–285, July 24, 2009 ª2009 Elsevier Inc. 271
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Figure 1. Mobilization or Inflammation Induces CD47 Upregulation in Hematopoietic Stem and Progenitor Cells
(A) Expression level of CD47 on cKit+ cells is shown for day 2 Cy/G-mobilized BM.
(B) Myeloid progenitor and stem cell gates are shown for day 2 mobilized BM. Histograms on right show level of CD47 expression in marrow LT-HSCs and GMPs
for steady state (light gray shaded histogram), day 2 mobilized (black line), and day 5 mobilized (dark gray shaded histogram).
(C) Relative MFI of CD47 for GMPs on days 0–5 of Cy/G mobilization. Results were normalized so that steady-state GMPs had MFI 100.
272 Cell 138, 271–285, July 24, 2009 ª2009 Elsevier Inc.
thus utilized the cyclophosphamide/G-CSF (Cy/G) protocol
(Morrison et al., 1997) to experimentally induce mobilization in
mice. We found that there was a notable increase of CD47 on
cKit+ bonemarrow cells on day 2 (Figure 1A), when bonemarrow
HSCs reach their maximum level, with CD47 increasing approx-
imately 4-fold by this time point (Figure 1B). The increase was
seen at all levels of the myeloid progenitor hierarchy, as long-
term hematopoietic stem cells (LT-HSCs) as well as granulo-
cyte-macrophage progenitors (GMPs) displayed this increase
in CD47 expression (Figure 1B). By day 5, when egress from
the marrow to distant marrow/spleen/liver sites had nearly
stopped, the levels of CD47 on the marrow HSC/progenitors
had returned to nearly normal levels. In Figure 1C, themean fluo-
rescence intensity of CD47 expression on GMPs is shown on
days 0 to 5 of mobilization.
These results predicted that mobilized human HSCs in the
blood would also have increased levels of CD47 on their cell
surfaces. We examined the CD47 expression level on human
bone marrow, cord blood (CB), and mobilized peripheral blood
(MPB) HSCs. The results show that human HSCs in circulation
have significantly higher levels of CD47 expression than sessile
HSCs (Figure 1E).
Endotoxins such as lipopolysaccharide (LPS) are also thought
to contribute to bone marrow mobilization (Cline and Golde,
1977) by causing activation of macrophages and a proinflamma-
tory response (Fenton and Golenbock, 1998), as well as
increasing the phagocytic capacity of macrophages (Wright
et al., 1989). We tested whether LPS administration in mice
would affect CD47 expression in stem and progenitor cells. Mir-
roring the pattern seen in Cy/G-induced mobilization, LPS
caused expansion of stem and progenitor cells by 2 days post-
treatment, followed by migration to the spleen and liver (Fig-
ure 1D). On day 2 after LPS administration, stem and progenitor
cells in the marrow had upregulated CD47 to a similar degree as
in Cy/G mobilization. By day 5, when the inflammatory response
had resolved, the levels of the protein had dropped to steady-
state levels (Figure 1D).
CD47 Upregulation during Mobilization Is Unlikely
to Be Necessary for Migration
Since CD47 was consistently upregulated in the mobilization
response, we tested the ability of stem and progenitor cells to
mobilize following Cy/G. TheCD47 knockout mouse has defects
inmigrationof neutrophils to sites of inflammation (Lindberget al.,
1996) and of dendritic cells to secondary lymphoid organs (Van
et al., 2006). The exact role of CD47 in migration of these cells
is unknown, but it may relate to poor integrin binding in the circu-
lation or lack of interactionwith SIRPaon endothelial cells. Hence
we reasoned that if CD47 was involved in the migration capacity
of these cells duringmobilization, then IAP/micewould display
reduced numbers of cells in the peripheral organs after Cy/G.
We thus administered Cy/G to both wild-type and knockout
mice and sacrificed mice on days 2–5. For each mouse, weanalyzed the number of stem and progenitor cells in peripheral
blood, marrow, spleen, and liver. We used the KLS (lineage-
negative, cKit-positive, Sca1-positive) population as a surrogate
for HSCs because the number of CD34 cells drops consider-
ably in proliferative states, making accurate calculation of LT-
HSC numbers difficult.
We found that there was little difference in numbers of mobi-
lized KLS or GMPs between wild-type and IAP/ mice (Fig-
ure 1F). There was a modest decrease in the ability of IAP/
mice to move progenitors to the spleen by day 3 (about 10-fold
less), but by days 4 and 5 they had restored normal numbers of
cells to the periphery. The marrow and liver compartments in
IAP/ had no difference in HSCs or GMPs from wild-type
mice. Additionally, there was no difference in HSC numbers in
peripheral blood by day 4 (data not shown). Hence, IAP/
mice do not have a significant mobilization defect. While this
result does not support a role for CD47 in the migration phase
of mobilization, it does not rule out a role for protection against
phagocytosis since macrophages from IAP/ mice also fail to
properly phagocytoseCD47-deficient cells, likely due to aberrant
macrophage education (Wang et al., 2007).
CD47-Deficient Mice Have No Gross Hematopoietic
Defect, but IAP/ HSCs Fail to Engraft Wild-Type Mice
We examined stem and progenitor frequencies in IAP+/ and
IAP/ mice. The relative frequency of cells in the stem and
myeloid progenitor compartment did not differ between these
mice and wild-type mice (Figure 2A). We then tested stem cells
from these mice for their ability to form colonies in an in vitro
assay. We examined colony formation at day 7 and found that
there was no major difference between wild-type and IAP/
stem cells in the number and type of colonies formed (Figure 2B).
We also tested whether bone marrow cells from IAP/ mice
could rescue recipient mice from the effects of lethal irradiation.
Typically, a dose of 2 3 105 bone marrow cells will rescue 100%
of recipient mice in this assay. In agreement with previous results
(Blazar et al., 2001), we found that IAP/ bone marrow could not
rescue these recipients (Figure 2C). However, administration of
these cells did prolong life span; normally, mice die between
day 12 and 15 after irradiation, but mice that received IAP/
bonemarrow lived about 7–10 days longer (Figure 2C). We do not
yet know the reason for the prolongation of life span in this case.
Next, we sorted Flk2 CD34 KLS stem cells from wild-type
and IAP/ cells and transplanted them into lethally irradiated
wild-type recipients along with 2 3 105 competitor cells. None
of the mice that received IAP/ HSCs had any engraftment of
donor cells, indicating that CD47 was indeed required to be
expressed intrinsically for the HSCs to transplant (Figures 2D
and 2E). We speculated that this was due to phagocytosis of
CD47 null cells, as has been shown for erythrocytes and
T cells. To test this, we enriched cKit+ cells from the bonemarrow
of wild-type and IAP/ mice and coincubated them with bone
marrow-derivedmacrophages. IAP/ stem and progenitor cells(D)Myeloid progenitor and stem cell gates are shown for day 2BMpost-LPS treatment. Histograms show level of CD47 expression on day 2 post-LPS (black line),
day 5 post-LPS (dark gray shaded histogram), steady state (light gray shaded histogram), and IAP/ (black shaded histogram).
(E) MFI for human CD47 on HSCs from human bone marrow (NBM), cord blood (CB), or mobilized peripheral blood (MPB).
(F) Evaluation of KLS cells in the hematopoetic organs of IAP+/+ and IAP/ mice mobilized on days 2 through 5. Two mice are analyzed per genotype per day.
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Figure 2. CD47-Deficient HSCs Are Efficiently Phagocytosed by Macrophages but Otherwise Exhibit Normal Hematopoietic Developmental
Potential
(A) Stem cells (left column) are gated on Lin cKit+ Sca1+ cells. Myeloid progenitors (right column) are gated on Lin cKit+ Sca1+ cells. Frequency in whole bone
marrow is shown adjacent to each gated population.
(B) Colony output on day 7 of individually sorted LT-HSCs. G: granulocyte; M: macrophage; GM: granulocyte and macrophage; GEMM: granulocyte, macro-
phage, erythroid, and megakaryocyte; Meg: megakaryocyte.
(C) Survival curve of recipient mice given lethal radiation and transplanted with the cells shown, n = 5 for each group.
(D) Examples of chimerism plots at 4 weeks post-transplant for IAP+/+ or IAP/ donors.
(E) Summary of chimerism analysis of mice transplanted with either 50 or 500 IAP+/+ or IAP/ cells.
(F) Results of phagocytosis assays using IAP+/+ or IAP/ cKit-enriched bone marrow. n = 3, error bars represent 1 standard deviation (SD).
(G) Photomicrographs of phagocytosis assays taken after 2 hr.were readily phagocytosed in this assay, whereas wild-type cells
were only minimally phagocytosed (Figures 2F and 2G). These
results were not due to increased apoptosis of the IAP/ cells
in these culture conditions, as there was no difference in Annexin
V positivity between the groups (Figure S4A available online).
We also tested HSC migration using the parabiosis model in
which two mice are joined surgically to allow their circulatory
systems to form anastamoses and a shared blood system274 Cell 138, 271–285, July 24, 2009 ª2009 Elsevier Inc.(Wright et al., 2001b). This model allows the examination of
migration in a more physiological setting because stem cells
are continuously seeded into the blood stream from the marrow
over time. We joined an IAP/mouse with a congenic wild-type
GFP+ mouse. For both pairs of mice that were parabiosed, bone
marrow HSC chimerism was seen in the IAP/ mouse but not
the wild-type mouse (Figure S1). Thus, IAP/ HSCs are cleared
even during physiological migration.
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Figure 3. IAP+/ HSCs Have a Competitive Disadvantage Relative to Wild-Type HSCs due to Macrophages
(A) MFI of CD47 on IAP+/+, IAP+/, and IAP/ LT-HSCs.
(B) Donor chimerism analysis for transplants of IAP+/+, GFP+ or IAP+/, GFP+ marrow cells. Loss of donor chimerism is shown using Kaplan-Meier curves.
(C) Experimental design for assessing effect of CD47 heterozygosity during LPS challenge.
(D) Change in percent chimerism of host KLS cells compared to expected chimerism based on peripheral blood granulocytes is shown. Error bars represent 1 SD
and p valueswere obtained by ANOVA statistics. n = 5 for IAP+/+with clodronate (CLOD), n = 7 for IAP+/+with control (CTRL), n = 4 for IAP+/with clodronate, n = 7
for IAP+/ with control.
(E) Results of in vivo phagocytosis assay comparing IAP+/+ and IAP+/ cKit-enriched cells. Percent recipient GFP+ F4/80 cells is shown (n = 3 for each group, error
bars represent 1 SD).CD47 Heterozygous HSCs Have Reduced Fitness
Relative to Wild-Type HSCs due to Macrophage
Clearance
Our observation that CD47 expression increases in states of
stress and mobilization led us to hypothesize that hematopoietic
stem and progenitor cells (HSPCs) that were genetically hemizy-
gous for CD47 might be more prone to phagocytosis and clear-
ance by macrophages over time, as has been seen for plateletsand erythrocytes (Olsson et al., 2005, 2007). Hence, we asked if
IAP+/ stem cells would be disadvantaged relative to wild-type
stem cells in long-term contribution to hematopoiesis. We first
analyzed the levels of CD47 expressed on IAP+/+, IAP+/, and
IAP/ stem cells. FACS analysis of CD34 Flk-2 KLS stem
cells revealed that the mean fluorescence intensity (MFI) of
CD47 on heterozygote HSCs was indeed at roughly half the level
of that on wild-type stem cells (Figure 3A).Cell 138, 271–285, July 24, 2009 ª2009 Elsevier Inc. 275
We then transplanted one cohort of sublethally irradiated
recipients with 2 3 106 wild-type whole bone marrow cells and
another with the same dose of IAP+/ bone marrow cells. Such
a dose would be expected to contain roughly 50–100 HSCs.
Since granulocyte chimerism in the peripheral blood is a good
surrogate marker of stem cell fitness (Bhattacharya et al.,
2006), we analyzed cells from the blood of these recipients at
periodic intervals. When wild-type marrow was transplanted
into wild-type recipients, granulocyte chimerismwasmaintained
for at least 40 weeks. However, when IAP+/ cells were trans-
planted, 4 out of 10mice lost donor chimerism over time, despite
having a successful engraftment initially (p = 0.0297, Figures 3B
and S2A). It was possible that there were fewer LT-HSCs per unit
of marrow in IAP+/ or IAP/ mice compared to wild-type. To
test if IAP/ mice had fewer functional HSCs, we transplanted
either IAP+/+ or IAP/ marrow cells into IAP/ donors. We
also cotransplanted IAP+/marrow into wild-type mice together
with wild-type marrow. We did not find any statistical difference
in donor granulocyte chimerism for up to 12 weeks in either case
(Figures S2B and S2C), indicating that there was not a demon-
strable deficit in stem cell numbers in IAP+/ or IAP/ mice.
Interestingly, the IAP+/ chimeras that did not lose donor
engraftment over time did not appear to have a quantitative
deficit in chimerism; rather they seemed to have levels of donor
cells similar to those in the wild-type chimeras (Figure S2A). We
thus hypothesized that physiological insults leading to chronic or
acute inflammatory states that occurred in some mice, but not
others, led to their losing IAP+/ donor chimerism over time,
but at steady state the donor IAP+/ cells were not affected.
To test this, we created chimeras by transplanting whole bone
marrow from either IAP+/+ GFP+ or IAP+/ GFP+ mice into suble-
thally irradiated wild-type syngeneic recipients. Since IAP/
mice have no known in vivo (Lindberg et al., 1996) or in vitro
(Figure 2B) defect in granulopoiesis, blood granulocyte chime-
rism can be used in this setting to estimate donor HSC engraft-
ment. After 12weeks, contribution of donor HSCswas assessed.
At this early time point, IAP+/ mice actually had a higher blood
granulocyte contribution, but there was considerable variation
within each group. The mice were challenged with a sublethal
dose of LPS (day 0), then given clodronate or control lipsomes
on day 2 and day 7. Clodronate liposomes have been shown
to specifically but transiently deplete marrow, spleen, and liver
macrophages when injected intravenously (Van Rooijen and
Sanders, 1994). At day 14, the mice were euthanized and
actual marrow KLS chimerism was assessed and compared to
expected chimerism based on blood granulocyte chimerism
(Figure 3D). Raw values are shown in Table S1. The results indi-
cate that there were more host (wild-type) KLS cells in the bone
marrow of the IAP+/ chimeras than expected. When macro-
phages were depleted, the chimerismwas at the level that would
be expected based on blood granulocyte chimerism. ANOVA
showed a significant interaction among IAP genotype (IAP+/+
versus IAP+/) and treatment with and without clodronate
(CLOD versus CTRL) (p = 0.0069). When the group including
the IAP+/ chimeras treated with control liposomes (IAP+/
CTRL) was excluded, there was no statistical difference between
the groups (p = 0.28). Analysis also showed that differences
between the treatment with and without clodronate were not276 Cell 138, 271–285, July 24, 2009 ª2009 Elsevier Inc.significant in IAP+/+ mice (p = 0.20) but were significant in IAP+/
mice (p = 0.011).
It was possible that these results were due to increased
apoptosis of IAP+/ cells relative to IAP+/+. To test this, we
measured the percent of Annexin V+ 7-AAD KLS cells in IAP+/+
and IAP+/ mice treated with LPS in the presence of control or
clodronate liposomes. There was no difference between the
groups (Figure S4B).
To establish that macrophages were indeed responsible for
clearing the cells with reduced CD47 expression, we challenged
donor IAP+/+,GFP+and IAP+/,GFP+micewith LPS.After 3days,
we harvested bone marrow from these mice and transplanted
cKit-enriched cells intrasplenically into GFP-negative wild-type
recipient mice similarly challenged with LPS 3 days prior. After
2 hr the recipient spleens were harvested and analyzed by
FACS. There were significantly more F4/80+ macrophages that
were GFP+ (representing macrophages containing phagocy-
tosed GFP+ cells) in mice injected with IAP+/ cells compared
to IAP+/+ (p < 0.0001, Figures 3E and S3).
CD47 Is Upregulated on Mouse Myeloid Leukemias
Previous microarray analysis had revealed that CD47 was signif-
icantly upregulated in leukemic Faslpr/lpr 3 hMRP8bcl2 trans-
genic bone marrow (Traver et al., 1998), and this was confirmed
in leukemic hMRP8bcr/abl 3 hMRP8bcl2 mice (Jaiswal et al.,
2003). Transcripts for CD47 were found by quantitative RT-PCR
to be increased in leukemic hMRP8bcr/abl 3 hMRP8bcl2 bone
marrow 3- to 4-fold and 6- to 7-fold in cKit-enriched leukemic
marrow relative to healthy hMRP8bcl2+ bonemarrow (Figure 4E).
Leukemic mice had an expansion of the GMP population as well
as cKit+ Sca1+ Lin stem and progenitor subsets in the spleen
relative to control mice, which were of the same genotype as
leukemic mice but failed to develop disease (Figures 4A–4D).
Expression levels for CD47 protein were found to begin
increasing in leukemic mice relative to control mice at the stage
of the Flk2 CD34 cKit+ Sca1+ Lin LT-HSC (Figure 4F) (Yang
et al., 2005). This increased level of expression was maintained
in GMP and Mac-1+ blasts but not megakaryocyte/erythroid
restricted progenitors (MEP) (Figure 4F). The increase in CD47
surface expression between leukemic and normal cells was
between 3- and 20-fold, depending on the sample and fluoro-
phore used (Figure S5C). We have observed increased CD47
expression in all mice that developed leukemia from
hMRP8bcr/abl 3 hMRP8bcl2 primary (n = 3) and secondary
transplanted mice (n = 3), Fas lpr/lpr 3 hMRP8bcl2 (Figure S4A)
primary (n = 14) and secondary (n = 19) mice, and hMRP8bcl23
hMRP8bcl2 primary (n = 3) and secondary (n = 12)mice.We have
also found increased CD47 expression in mice that received
p210bcr/abl retrovirally transduced mouse bone marrow cells
and then developed leukemia (Figure S5B).
CD47 Expression on Normal and Leukemic Human Stem
Cells
Becausewe found CD47 to be increased on all mouse leukemias
we examined, we investigated CD47 expression on normal and
dysplastic human hematopoietic cells. FACS-mediated analysis
of human hematopoietic progenitor populations was performed
on blood- and marrow-derived cells from normal CB and MPB
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Figure 4. CD47 Is Upregulated in Murine and Human Myeloid Leukemia
Typical stem and progenitor plots are shown for leukemic hMRP8bcrabl 3 hMRP8bcl2 cells compared to control nonleukemic animals. Lin cKit+ Sca1+ gated
cells from control bone marrow (A) and leukemic spleen (B) and Lin cKit+ Sca1 gated cells from control bone marrow (C) and leukemic spleen (D). Frequency is
shown as a percentage of entire marrow or spleen mononuclear fraction.
(E) Quantitative RT-PCR for CD47. Data are shown from three sets of mice transplanted with either leukemic or control hRMP8bcrabl3 hMRP8bcl2 BM cells and
then sacrificed 2–6 weeks later. Results were normalized to beta-actin and 18S rRNA expression. Fold change relative to control transplanted whole Bcl-2+ BM
cells was determined. Error bars represent 1 SD.
(F) Histograms show expression of CD47 on gated populations for leukemic (gray) and control (black) mice.
(G) Comparative FACS histograms of human CD47 expression by normal (red; n = 6) and acute myeloid leukemic (AML, blue; n = 6) hematopoietic stem cells
(HSCs; CD34+CD38CD90+Lin) and progenitors (CD34+CD38+Lin).
(H) Comparative FACS histograms of CD47 expression by normal (red) and chronic myeloid leukemia (blue) hematopoietic stem cells (HSCs;
CD34+CD38CD90+Lin), committed progenitors (CD34+CD38+Lin), and Lin+ cells.Cell 138, 271–285, July 24, 2009 ª2009 Elsevier Inc. 277
(n = 16) and myeloproliferative disorders (MPDs) including poly-
cythemia vera (PV; n = 16), myelofibrosis (MF; n = 5), essential
thrombocythemia (ET; n = 7), chronic myelomonocytic leukemia
(CMML; n = 11), and atypical chronic myeloid leukemia (aCML;
n = 1), as well as myeloid blast crisis (BC) phase chronic myeloid
leukemia (CML; n = 19), chronic phase CML (n = 7), and acute
myeloid leukemia (AML; n = 13). This analysis demonstrated
that the GMP population was expanded in MPDs with myeloid
skewed differentiation potential including atypical CML, prolifer-
ative phase CMML, and acute leukemia including blast crisis
CML and AML (Figures S6A and S6C). AML HSCs and progeni-
tors uniformly exhibited higher levels of CD47 expression
compared with normal controls (Figure 4G); every sample from
CML-BC (n = 19) and AML (n = 13) had elevated levels of
CD47. Moreover, progression from chronic phase CML to blast
crisis was associated with a significant increase in CD47 expres-
sion (Figure 4H). Using the methods described in this study, we
have found that human CD47 protein expression in CML-BC
increased 2.2-fold in CD90+ CD34+ CD38 Lin cells relative to
normal CB and MPB (p = 6.3 3 105), 2.3-fold in CD90
CD34+ CD38Lin cells relative to normal (p = 4.3 3 105),
and 2.4-fold in CD34+ CD38+ Lin cells (p = 7.63 106) (Figures
4G, 4H, and S6B). Since CB and MPB HSCs have almost double
the amount of CD47 as normal marrow (Figure 1E), these figures
likely underestimate the true increase in CD47 compared to
normal marrow.
We also examined CD47 expression in other myeloprolifera-
tive disorders, such as polycythemia vera, post-polycythemic
myeloid metaplasia with myelofibrosis, essential thrombocythe-
mia, agnogenic myeloid metaplasia, and chronic myelomono-
cytic leuekmia. None of the samples we examined from these
disorders displayed increased CD47 (data not shown). It is likely
that the fixed, high expression of CD47 on AML cells and
CML-BC cells represents a late event in malignant progression,
whether by genetic or epigenetic heritably increased expression.
A summary of all the human samples analyzed is shown in
Table S2.
CD47 Expression Can Rescue the In Vivo Growth Defect
of the AML Cell Line MOLM-13 via a Mechanism Other
Than Migration
In order to experimentally test the significance of elevated CD47
expression on myeloid leukemias, we decided to examine
whether the level of CD47 expressed on myeloid leukemia could
affect its pathogenicity in vivo. We first screened a panel of
human AML cell lines for human CD47 expression. On the basis
of this analysis, we found significant variation in the amount of
cell surface CD47 (adjusted for cell size) in the varying lines
(Figures S7A and S7B). We then tested whether there was vari-
ation in the ability of some of these cell lines to engraft in immu-
nocompromised mice. Human HL-60 and Kasumi-1 cells, which
express moderate to high levels of human CD47, were able to
engraft C57Bl/6 or Balb/c recombination-activating gene 2,
common gamma chain-deficient (RAG2/, gc/) mice (Figures
S6C and S6D), which are reported to have little or no interaction
between their SIRPa and human CD47 (Takenaka et al., 2007).
MOLM-13 cells, which are derived from a patient with AML 5a,
have low endogenous CD47 expression and were unable to278 Cell 138, 271–285, July 24, 2009 ª2009 Elsevier Inc.engraft in either of these strains. Even when transplanted into
nonobese diabetic severe combined immunodeficiency, inter-
leukin 2 receptor common gamma chain/ (NOG) mice that
are reported to have more effective interaction between their
mouse SIRPa and human CD47, and thus should be permissive
for human donor cells (Takenaka et al., 2007), MOLM-13 cells
failed to engraft (Figure S7C).
Since MOLM-13 cells failed to engraft in any of the mouse
models tested, we decided to use them for further analysis of
the role of CD47 in leukemogenicity. MOLM-13 cells were trans-
duced with either control (Tet) or CD47-expressing (Tet-CD47)
lentiviruses (Figure 5A), and stable integrants were propagated
on the basis of GFP expression. We first tested if ectopic expres-
sion of the murine CD47 (muCD47) protein could rescue the
growth defect of these cells. The cells were transplanted intrave-
nously in a competitive setting with untransduced MOLM-13
cells into T-, B-, and NK-deficient RAG2/, gc/ mice. Only
cells transduced with Tet-CD47 were able to give rise to tumors
in these mice, efficiently engrafting bone marrow, spleen, liver,
and peripheral blood (Figures 5B and 5C).
Since CD47 has been reported to be important for the migra-
tion of hematopoietic cells, one possibility for the lack of growth
of Tet MOLM-13 cells in mice was their inability to migrate to
niches. To test this, Tet MOLM-13 or Tet-CD47 MOLM-13 cells
were directly injected into a single femoral cavity of immunode-
ficient Balb/c mice. Tet-CD47 MOLM-13 cells were able to
spread to all bones and other hematopoietic tissues of recipient
mice and lead to death, whereas Tet MOLM-13 cells had
minimal, if any, engraftment and only at the site of injection,
without morbidity by 75 days after transplant (Figures 5D–5F).
These results suggested a function other than or in addition to
migration for CD47 in MOLM-13 engraftment.
The Level of CD47 Expressed on MOLM-13 Cells
Determines Tumorigenic Potential
Our results up to this point had indicated that ectopically
expressing muCD47 on a nonengrafting human cell line could
rescue its growth defect. These experiments did not, however,
answer whether the level of CD47 expressed on a leukemic
cell could affect its tumor-forming potential. Tomodel the tumor-
igenic effect of having high versus low CD47 expression, we
sorted clones of muCD47 expressing MOLM-13 cells into high
and low expressors. When adjusted for cell size, CD47 density
on the CD47lo MOLM-13 cells was approximately equal to
mouse bone marrow cells, whereas CD47hi MOLM-13 cells
had 9-fold higher expression, an increase commensurate with
the change seen in CD47 expression on primary leukemic cells
compared to their normal counterparts (Figures 6A and 6B).
When high- or low-expressing cells were transplanted into recip-
ients, only mice transplanted with high-expressing cells suc-
cumbed to disease by 75 days of age (Figure 6C). Furthermore,
organomegaly was more pronounced in these mice (Figure 6D).
As expected, the infiltration of MOLM-13 cells in bone marrow
and spleen of recipient mice was also much higher for mice
transplanted with CD47hi MOLM-13 cells as well (Figure 6E).
We also examined the level of CD47 expression in two mice
that received CD47lo MOLM-13 cells but had significant marrow
engraftment. In both cases, the persisting cells after 75 days had
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Figure 5. Overexpression of Murine CD47 Rescues the Growth Defect of MOLM-13 Myeloid Leukemia Cells
(A) GFP and humanCD45 chimerism formice transplantedwith untransducedMOLM-13 cells (53 105) and either 53 105 Tet (n = 6) or Tet-CD47MOLM-13 (n = 8)
cells.
(B) MOLM-13 chimerism in hematopoietic tissues was determined by human CD45 chimerism and measurement of tumor lesion size.
(C) Hematoxylin and eosin sections of Tet-CD47 MOLM-13 transplanted liver (2003) (top panel). Periportal (arrow) and sinusoidal (arrowhead) tumor infiltration is
evident. Examples of liver tumor formation and hepatomegaly in Tet-CD47 MOLM-13 transplanted mice versus control transplanted mice (middle panel). GFP
fluorescence demonstrates tumor nodule formation as well diffuse infiltration (bottom panel).
(D) 13 106 Tet (n = 5) or Tet-CD47MOLM-13 (n = 4) cells were injected into the right femur of RAG2/, Gc/mice and the tissueswere analyzed 50–75 days later
for chimerism of MOLM-13 cells in BM.
(E) Survival curve of mice transplanted intrafemorally with Tet or Tet-CD47 MOLM-13 cells.
(F) Representative FACS plots from mice transplanted intrafemorally with Tet or Tet-CD47 MOLM-13 cells. R, right; L, left.much higher levels of CD47 than the original line (Figure 6F), indi-
cating that a strong selection pressure exists in vivo for high
levels of CD47 expression on MOLM-13 leukemia cells.
We were also able to modulate CD47 expression with doxycy-
cline because we utilized the Tet-responsive (Tet-OFF) promoter
element to control expression of CD47 in MOLM-13 cells. Begin-
ning 2 weeks after transplantation with CD47hi MOLM-13 cells,
a cohort of mice was given doxycycline to extinguish CD47
expression and followed for up to 75 days post-transplant.During this time, none of the mice given doxycycline succumbed
to disease or had large infiltration of MOLM-13 cells in hemato-
poietic organs (Figures 6D and 6E) other than 1–2 large extrapar-
enchymal masses seen in the livers. At the dose of doxycycline
used in this experiment, muCD47 expression in MOLM-13 cells
was reduced to levels below that of normal mouse bone marrow
but notably was not completely absent (Figure 6B). Thus, a sus-
tained high level of CD47 expression is required for robust
MOLM-13 growth in hematopoietic organs.Cell 138, 271–285, July 24, 2009 ª2009 Elsevier Inc. 279
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Figure 6. Higher Expression of CD47 on MOLM-13 Cells Causes Increased Tumorigenicity
(A) Histograms show CD47 expression in MOLM-13 high (black), MOLM-13 low (gray), and mouse bone marrow (shaded) cells, with MFI normalized for size
shown.
(B) The histograms show level of CD47 expression on CD47hi MOLM-13 cells in untreated (shaded) and doxycycline-treated (shaded) mice, with MFI normalized
for size shown.
(C) Survival of mice transplanted with 13 106 CD47hi MOLM-13 cells, CD47lo MOLM-13 cells, or CD47hi MOLM-13 cells with doxycycline administration started
after 2 weeks post-transplant. n = 5 for CD47hi and CD47hi plus doxycycline. n = 10 for CD47lo.
(D) Liver and spleen size of mice at necropsy or 75 days after transplant with 13 106 CD47hi MOLM-13 cells, CD47lo MOLM-13 cells, or CD47hi MOLM-13 cells
with doxycycline.
(E) Bonemarrow and spleen chimerismof human cells inmice at necropsy or 75 days after transplant with 13 106CD47hiMOLM-13 cells, CD47loMOLM-13 cells,
or CD47hi MOLM-13 cells with doxycycline.
(F) Murine CD47 expression on CD47lo MOLM-13 cells engrafting in bone marrow (open) compared with original cell line (shaded), with MFI normalized for size
shown.
(G) Bone marrow and (H) liver histograms are shown for MOLM-13 cells in mice 35 days after transplant with 1 3 106 CD47lo MOLM-13 cells. Parental Tet
MOLM-13 (dark gray shaded) and Tet CD47lo MOLM-13 CD47 (light gray shaded) expression, as well as engrafting cells in the clodronate (gray line) and control
(black line) cohorts, is displayed in the histograms.
(I) MFI of CD47 channel in engrafting MOLM-13 cells in clodronate (CLOD) or control (CTRL) treated mice is shown for bone marrow and liver. Error bars
represent 1 SD.280 Cell 138, 271–285, July 24, 2009 ª2009 Elsevier Inc.
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Figure 7. Increasing CD47 Expression on MOLM-13 Cells Confers Increasing Ability to Evade Macrophage Phagocytosis
(A) Tet, Tet-CD47lo, Tet-CD47 bulk, or Tet CD47hi MOLM-13 cells were incubated with bonemarrow-derivedmacrophages (BMDM) for 2 hr and phagocytic index
was determined. Error bars represent 1 SD (n = 6 for each time point).
(B) Photomicrographs of BMDMs incubated with Tet or Tet-CD47 MOLM-13 cells at 2 and 24 hr (4003).
(C) CD47hi GFP and CD47lo MOLM-13 RFP cells were coincubated with BMDMs for 2 hr. Phagocytic index is shown for three separate samples for CD47hi GFP
(green) and CD47lo MOLM-13 RFP (red) cells.
(D) Photomicrographs show brightfield (top left), RFP (top right), GFP (bottom left), and merged (bottom right) images of CD47hi GFP and CD47lo MOLM-13 RFP
cells that were coincubated with BMDMs for 24 hr.Macrophages Mediate Selective Pressure for CD47hi
Variants of MOLM-13 Cells
Because we had observed that mice transplanted with CD47lo
MOLM-13 cells had selection over time for higher-expressing
clones in vivo, we wondered if this selection pressure was medi-
ated by macrophages. To test this, we used clodronate lipo-
somes to deplete macrophages prior to and after transplant of
CD47lo MOLM-13 cells and sacrificed mice after 5 weeks.
When control liposomes were used, the level of CD47 increased
significantly on the engrafted human cells. However, when clodr-
onate-containing liposomes were used, the expression of CD47
onMOLM-13 cells wasmaintained at the level of the parental line
(Figures 6G–6I). Thus, macrophages mediate selective pressure
for high-expressing CD47 clones in vivo.
Interestingly, when clodronate was used to deplete macro-
phages in the immunodeficient mice, the level of engraftment
was comparable between the control Tet MOLM-13 cells and
the CD47 MOLM-13 cells (Figure S8), suggesting that depletion
of macrophages could compensate for lack of CD47 expression
on MOLM-13 cells as well.Ability to Evade Macrophage Phagocytosis Correlates
with CD47 Expression Level
We incubated Tet (vector only), bulk (unsorted) Tet-CD47, Tet-
CD47hi, or Tet-CD47loMOLM-13 cells with bonemarrow-derived
macrophages (BMDM) for 2–24hrandassessedphagocytosisby
counting the number of ingested GFP+ cells under a microscope
(Figures 7A and 7B) or by evaluating the frequency of GFP+
macrophages by flowcytometry (Figure S9A). Therewas a strong
correlation between level of CD47 expressed and the likelihood
of phagocytosis (Figure 7A). When CD47lo RFP and CD47hi GFP
MOLM-13 cellswere coincubatedwithmacrophages in the same
wells, the low-expressing cells were far more likely to be phago-
cytosed (Figures 7C and 7D). Thus, in a mixed population of cells
with varying levels of CD47 expression, the low expressiors were
more likely to be cleared by macrophages over time. These
results were not due to differences in apoptosis between
CD47-expressing and control MOLM-13 cells, as both groups
had similar levels of Annexin V positivity in vitro (Figure S4C).
We also injected MOLM-13 cells into mice and analyzed
hematopoietic organs 2 hr later for evidence of macrophageCell 138, 271–285, July 24, 2009 ª2009 Elsevier Inc. 281
phagocytosis. Macrophages in bone marrow, spleen, and liver
all had a higher GFP+ fraction when injected with Tet MOLM-13
cells as compared to muCD47-expressing cells, indicating that
the muCD47 cells were more likely to be phagocytosed in vivo
as well (Figure S9B).
Finally, we asked if inhibiting macrophage SIRPa using a
blocking antibody could abrogate the protection against phago-
cytosis that CD47 provided MOLM-13 cells. Indeed, when this
receptor was blocked, CD47-expressing MOLM-13 cells were
phagocytosed at the same rate as control MOLM-13 cells
(Figure S10).
DISCUSSION
Physiological Significance of CD47 Upregulation
We demonstrate here that HSPCs upregulate CD47 in response
to an insult that induces mobilization. This then leads to the
surprising finding that HSPCs themselves are regulated by
phagocytosis in vivo. Hence, our results indicate that protection
from phagocytosis is essential for HSC survival during migration
to the periphery after a strong mobilizing or inflammatory stim-
ulus. A recent report indicates that HSPCs can circulate through
the lymphatic system as well (Massberg et al., 2007). It will be
interesting to see if these HSPCs upregulate CD47 to evade
the numerous sinusoidal macrophages in lymph nodes.
Since leukemias upregulate CD47 as well, it appears that they
co-opt this normal physiological response to stress-induced
mobilization as a means to protect themselves at the expense
of normal, non-neoplastic progenitors. In this manner, leukemic
stem cells could quickly gain a survival advantage over normal
stem cells, leading to their eventual take-over of the hematopoi-
etic environment.
The regulatory mechanisms for CD47 expression in mobiliza-
tion and leukemia remain unknown. The fact that CD47 is upre-
gulated and downregulated in such a temporally precise manner
during mobilization suggests that there is tight control over its
expression in normal physiology. Leukemias, however, seem
to have constitutively high CD47 expression. The only published
regulator of CD47 expression is the transcription factor nuclear
respiratory factor 1 (Nrf1) (Chang and Huang, 2004). It remains
to be determined if Nrf1 or other regulatory elements are involved
in the progression of human myeloid leukemia, and if there is
a common regulatory pathway that operates in mobilization
as well.
Macrophages Are Important Mediators of Tumor
Immunosurveillance
Many examples of tumor clearance by T, B, and NK cells have
been described in the literature, indicating that a healthy immune
system is essential for regulating nascent tumor growth.
However, to date, few examples indicating that macrophage-
mediated phagocytosis can check tumor development have
been produced. Collectively, our studies reveal that ectopic
overexpression of CD47 can enable otherwise immunogenic
tumor cells to grow rapidly in a T, B, and NK cell-deficient
host. Furthermore, this is likely to reflect a mechanism used by
primary human myeloid leukemias to evade the host immune
system since CD47 is upregulated in nearly all sufficiently282 Cell 138, 271–285, July 24, 2009 ª2009 Elsevier Inc.advanced murine and human myeloid leukemias examined
thus far.
This form of immune evasion is particularly important since
these cancers occupy sites of high macrophage infiltration.
The leukemias studied here are clonal yet found throughout the
marrow (and in mouse, spleen, and liver); these are organs
with abundant intra-tissue macrophages as well as macro-
phage-lined sinusoids at the entry site of circulating blood cells.
CD47was first cloned as an ovarian tumor cell marker, indicating
that it may play a role in preventing phagocytosis of other tissue
cancers as well (Campbell et al., 1992). Furthermore, solid
tumors often metastasize to macrophage-rich tissues such as
liver, lung, bone, and lymph nodes, indicating that they must
be able to escape macrophage-mediated killing in those tissues.
Preventing CD47-SIRPa interaction could be doubly effective
because antigens from phagocytosed tumor cells may be
presented by professional antigen-presenting cells such as
macrophages or dendritic cells to activate an adaptive immune
response, leading to further tumor destruction.
CD47 May Be Upregulated because Some Cancers
Are More Immunogenic Than Normal Tissue
But why would leukemic progenitor cells require additional
protection against phagocytosis? Like aged neutrophils or eryth-
rocytes, tumor cells can display signs of cellular ‘‘damage’’ and/
or glycosidic variations on their cell surface. There arewell-estab-
lished data that tumors can be recognized by NK cells via ligands
that mark ‘‘stressed self’’ (Gasser et al., 2005). We propose that
leukemic cells likewise express stress ligands that mark them
for phagocytosis; by upregulating CD47, this innate immunity
check on tumor growth can be circumvented. One of these
pro-phagocytic ligands, calreticulin, is known to be upregulated
in aged cells. It has been shown that its effects can be counter-
acted by expression of CD47 (Gardai et al., 2005). It remains to
be seen if this or other stress ligands are expressed on nascent
leukemic cells to mark them for destruction.
Therapeutics Targeting CD47 May Be Clinically Useful
for Treating Cancer
Others have shown that antibodies that crosslink CD47 on the
surface of chronic lymphocytic leukemia cells can induce a cas-
pase-independent cell death (Mateo et al., 1999; Uno et al.,
2007). This phenomenon, while promising, appears to function
primarily by inducing apoptosis, not necessarily by promoting
phagocytosis. In fact, we show in a companion paper (Majeti
et al., 2009 [this issue of Cell]), that anti-CD47 blocked CD47hi
human AML cells are phagocytosed by macrophages, without
first becoming apoptotic.
In addition, our recent results in human AML indicate that
increasing CD47 transcript levels are associated with shortened
survival (Majeti et al., 2009), allowing the level of expression of this
gene to potentially be used as an independent prognostic vari-
able. Combined with the data presented here, where we show
that CD47 expression levels affect the fitness of both normal
HSCs and leukemic cells, we propose that CD47 is a compelling
target for therapeutic strategies that reduce its functional interac-
tion with macrophage SIRPa and thus render these cancers
susceptible to innate and adaptive immune system clearance.
EXPERIMENTAL PROCEDURES
Mice
CD47-deficient IAP/mice on aC57Bl/6 background were obtained from Eric
Brown and bred onto our wild-type colony. IAP/mice were crossed to beta-
actin GFP (Wright et al., 2001a) or CD45.1 C57Bl/6 mice from our colony to
obtain GFP+ or congenic strains. hMRP8bcrabl, hMRP8bcl2, and Faslpr/lpr
transgenic mice were obtained as previously described (Traver et al., 1998;
Jaiswal et al., 2003). C57Bl/6 mice from our colony were used as a source
of wild-type cells. C57Bl/6 or Balb/c RAG2/ common gamma chain (Gc)/
mice were bred in our laboratory. NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NOG)
mice were obtained from The Jackson Laboratory and bred in a pathogen-
free environment at our facility. For transplant experiments, cells were trans-
planted into either immunodeficient mice given a radiation dose of 4 Gy using
gamma rays from a cesium irradiator (Phillips), or CD45.2 C57Bl6/Ka mice
given a radiation dose of 9.5 Gy. Sublethal radiation was given at a dose of
4.75 Gy. Mice were euthanized when moribund.
Cells were injected via tail vein in sterile PBS using a 27-gauge needle. Donor
and recipient mice were 6–12 weeks of age. Parabiosis was performed as
previously described (Wright et al., 2001b). Mice were mobilized with cyclo-
phosphamide (Sigma) (200 mg/kg) and G-CSF (Neupogen) (250 mg/kg) as
previously described (Morrison et al., 1997). Bacterial LPS from E. coli
055:B5 (Sigma) was administered at a dose of 40 mg/kg into the peritoneal
cavity.
Cell Lines
MOLM-13 cells were obtained from DSMZ. HL-60, Jurkat, U937, K562, and
Kasumi-1 cells were obtained from ATCC. Cells were maintained in Iscove’s
modified Dulbecco’s media (IMDM) plus 10% fetal bovine serum (FBS)
(Hyclone).
Quantitative RT-PCR Analysis
Bone marrow was obtained from leukemic hMRP8bcr/abl3 hMRP8bcl2 mice
or hMRP8bcl2 control mice. Cells were cKit enriched using cKit microbeads
and an autoMACS column (Miltenyi) and cDNA was created from RNA using
standardmethods (Invitrogen, SuperScript II). cDNA corresponding to approx-
imately 1000 cells was used per PCR reaction. Quantitative PCR was per-
formed with a SYBR green kit on an ABI Prism 7000 PCR (Applied Biosystems)
machine.
Cell Staining and Flow Cytometry
Mouse tissues were prepared and stained for stem, progenitor, and peripheral
blood cells as previously described (Akashi et al., 2000; Yang et al., 2005;
Bhattacharya et al., 2006). Mouse CD47 antibody (clone mIAP301, ATCC)
was assessed using biotinylated antibody produced in our lab followed by
staining with streptavidin-conjugated Quantum Dot 605 (Chemicon). Samples
were analyzed using a FACSAria (Beckton Dickinson).
Normal human bone marrow and blood samples were obtained with
informed consent from 20- to 25-year-old paid donors who were hepatitis A,
B, C, and HIV negative by serology (All Cells). Leukemic blood and marrow
cells were obtained with informed consent from previously untreated patients
at Stanford University Medical Center according to IRB approved methods.
HSCs and progenitors were stained and identified as previously described
(Manz et al., 2002). Anti-human CD47 FITC (clone B6H12, PharMingen) was
used to assess CD47 expression in all human samples. Following staining,
cells were analyzed using a modified FACS Vantage (Becton Dickinson) or a
FACSAria.
Engraftment of MOLM-13 cells was assessed by using anti-human CD45
PE-Cy7 (PharMingen), anti-mouse CD45.2 APC (clone AL1-4A2 produced in
our lab), and anti-mouse CD47 Alexa-680 (mIAP301, produced in our lab).
All samples were resuspended in propidium iodide containing buffer before
analysis to exclude dead cells. FACS data was analyzed using FloJo software
(Treestar).
Lentiviral Preparation and Transduction
pRRL.sin-18.PPT.Tet07.IRES.GFP.pre, CMV, VSV, and tet trans-activator
(tTA) plasmids were obtained from Luigi Naldini (Vigna et al., 2002). The full-length murine cDNA for CD47 form 2was provided by Eric Brown (Genentech).
Plasmid DNA was transfected into 293T cells and supernatant harvested and
concentrated by standard protocols. Cells were transduced with lentivirus for
48 hr andGFP+ cells were sorted to purity and grown for several generations to
ensure stability of the transgenes.
In Vitro Phagocytosis Assays
Bone marrow-derived macrophages were prepared and harvested by incuba-
tion in trypsin/EDTA (GIBCO) for 5 min and gentle scraping. Macrophages
were plated at 5 3 104 cells per well in a 24-well tissue culture plate (Falcon)
for 24 hr. Fresh media were added 2 hr before 2.5 3 105 target cells were
added to the macrophage-containing wells and incubated at 37C for the indi-
cated times. After coincubation, wells were washed thoroughly with IMDM
three times and examined under an Eclipse T5100 (Nikon) using an enhanced
green fluorescent protein (GFP) or Texas Red filter set (Nikon). Phagocytic
index was calculated using the following formula: phagocytic index = number
of ingested cells/(number of macrophages/100). At least 200 macrophages
were counted per well.
Macrophage Depletion
Clodronate was a gift of Roche Diagnostics GmbH. It was encapsulated in
liposomes as previously described (Van Rooijen and Sanders, 1994). Macro-
phages were depleted by injecting intravenously (i.v.) 200 ml of the final
liposome preparation 48 hr prior to cell transplant. Mice were injected with
100 ml every week thereafter to maintain depletion until they were euthanized.
Statistics
Statistics were calculated using Prism 4.0 software (GraphPad Software, Inc.)
The Welch corrected student’s t test was used to calculate all column statis-
tics. Two-tailed p values are shown in figures. For survival curves, p values
were obtained using a logrank test. For comparison of groups, one-way
ANOVA and tests of contrast were used where indicated.
Additional Experimental Procedures are available in Supplemental Data.
SUPPLEMENTAL DATA
Supplemental Data include two tables, ten figures, and Supplemental Experi-
mental Procedures and can be found with this article online at http://www.cell.
com/supplemental/S0092-8674(09)00651-5.
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